Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685353 | 0.69 | — | — | |
| SCHEMBL3490997 | 0.68 | NPSR1 (0.36) | NPSR1MAPTGAAKDM4EALDH1A1 | |
| SCHEMBL8715949 | 0.64 | NPSR1 (0.30) | NPSR1 | |
| SCHEMBL31405560 | 0.61 | KMT2A (0.41) | KMT2A | |
| SCHEMBL11257705 | 0.61 | — | — | |
| SCHEMBL3466593 | 0.61 | — | — | |
| SCHEMBL3466146 | 0.61 | — | — | |
| SCHEMBL11325634 | 0.61 | — | — | |
| SCHEMBL6632296 | 0.59 | CRBN (0.30) | — | |
| SCHEMBL10875623 | 0.59 | NPSR1 (0.41) | NPSR1MAPTGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3344625-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | Lysosomal Therapeutics Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3344625-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | Lysosomal Therapeutics Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040879-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040879-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2008149311-A1 | USE OF DERIVATIVES OF 3-OXO-2,3-DIHYDRO-5H-THIAZOLOF[3,2-A]PYRIMIDINE OR OF 3-OXO-2,3-DIHYDRO-5H-SELENAZOLO[3,2-A]PYRIMIDINE OR OF 3-OXO-1,2,3-TRIHYDRO-5H-IMIDAZOLO[1,2-A]PYRIMIDINE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF CANCER | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-12-11 | — | — | WO | disclosed |
| EP-2000140-A1 | Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000140-A1 | Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-4491587-A | ANTIALLERGENS, ANTIHISTAMINES, MUSCLE RELAXANTS/ INSULATING POWDER BLANKET ABOVD THE MELT WITH HEAT GENERATED IN THE MELT BY ELECTRIC CURRENT; LOWER TEMPERATURE | MEAD JOHNSON & COMPANY (US) | 1985-01-01 | — | — | US | disclosed |
| US-4223031-A | ANTIALLERGENS, ANTIHISTAMINES, BRONCHODILATOR AGENTS, HYPERSENSITIVITY | MEAD JOHNSON & COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | PARK7, GAA, TYMP | NPSR1 2944/4885MAPT 116/4885GAA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.